Yinkang-007

N/A

Report date: 2025/03/20 09:21:12

Base Information

Drug NameYinkang-007
Drug Alias Namedenosumab biobetter (Yinkang Biopharma)anti-RANKL biobetter (Yinkang Biopharma)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor ligand superfamily member 11 inhibitors
TargetsTumor necrosis factor ligand superfamily member 11
Therapy Area/IndicationsOsteoporosis, Postmenopausal
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesYinkang Biopharma Inc.
China Registration ClassN/A

Develop Information

Active CompaniesYinkang Biopharma Inc.
Inactive CompaniesN/A
Active IndicationsOsteoporosis, Postmenopausal
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A